ClinicalTrials.gg
Not yet recruitingNCT07742683Updated Aug 3, 2026

Digital Psychosocial Interventions on Stigma and Health Outcomes in TB Patients

An interventional study of Online Mindfulness and Online CBT Intervention in Tuberculosis (TB), sponsored by Peking Union Medical College. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Peking Union Medical College · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
496
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study addresses the shortcomings of routine clinical management for tuberculosis (TB) patients by proposing psychosocial interventions targeting stigma, while investigating the current status of stigma, psychological issues, medication adherence, and drug resistance among tuberculosis patients. It analyzes the underlying mechanisms, integrates online mindfulness courses, digital cognitive behavioral therapy (CBT), and human-machine interactive dialogue modules to develop a digital psychosocial intervention platform. Through a randomized controlled trial, the study validates the impact of the platform on stigma and health outcomes among tuberculosis patients in China. Ultimately, the research aims to formulate a scalable digital psychosocial intervention technical solution, providing evidence-based support for optimizing China's comprehensive tuberculosis prevention and control model.

02

Conditions studied

  • Tuberculosis (TB)

Keywords

  • Tuberculosis
  • Digital Psychosocial Interventions
  • Stigma
  • Online Mindfulness Courses
  • Cognitive Behavioral Therapy
  • Human-computer Interaction
03

In context

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

This study's planned enrollment of 496 is above the median of 150 across 820 interventional studies indexed under Tuberculosis.

Browse Tuberculosis studies →

Lead sponsor

Peking Union Medical College is the lead sponsor of 58 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

1. Inclusion Criteria

  1. Aged 18 years or older.
  2. Patients diagnosed with active pulmonary tuberculosis within the past 1 year via bacteriological tests (smear microscopy or culture) and/or molecular biological assays (e.g., GeneXpert).
  3. Capable of independently completing questionnaires and scale assessments; accessible for sputum collection, chest radiography, biomarker testing and other examinations.
  4. Provided full for the entire study and signed the written informed consent form.

2. Exclusion Criteria

  1. Presence of severe chronic diseases such as immune system disorders, or severe neurological and psychiatric disorders.
  2. No access to electronic devices required for subsequent online intervention.
  3. Cognitive impairment or hearing loss that impairs normal communication and prevents cooperation with surveys and intervention procedures.
  4. Concurrent participation in other health promotion or clinical intervention studies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
496 participants (estimated)

Study arms

  • Experimental
    Online Mindfulness Intervention Group

    Participants in this group received a 6-week online mindfulness course delivered twice weekly.

    Behavioral: Online Mindfulness

  • Experimental
    Online CBT Intervention Group

    Participants in this group received a 6-week online CBT intervention course delivered twice weekly.

    Behavioral: Online CBT Intervention

  • Experimental
    Human-computer Interaction Intervention Group

    The patients in this group are required to use the human-computer interaction system developed by our research institute for a duration of 6 weeks, with a frequency of no less than 2 use per week and a duration of no less than 20 minutes per use.

    Behavioral: Human-computer Interaction

  • Active comparator
    Control Group

    Patients in the control group continued to receive routine treatment and management services provided by the tuberculosis prevention and control system throughout the study period. No additional psychosocial services or digital health services were offered beyond routine psychological support.

    Behavioral: Routine treatment and management services provided by the tuberculosis prevention and control system

Interventions

  • BehavioralOnline Mindfulness

    The 6-week online mindfulness course developed by our research team consists of theoretical lectures plus practice audio and video materials, with 2 sessions delivered per week.

  • BehavioralOnline CBT Intervention

    The 6-week online cbt course developed by our research team consists of 12 video materials, with 2 sessions delivered per week.

  • BehavioralHuman-computer Interaction

    The human-computer interaction mini-program named Xiexin Xiangban, developed by the research team.

  • BehavioralRoutine treatment and management services provided by the tuberculosis prevention and control system

    routine treatment and management services provided by the tuberculosis prevention and control system

06

What researchers measure

Primary outcomes

  1. Stigma: Tuberculosis-related Stigma Scale (TSS)

    The tuberculosis-related stigma scale (TSS) was adopted in this study to quantitatively assess the level of tuberculosis-related stigma among participants.The scale consists of 9 items in total with a total score range of 0 to 27 points. Higher scores on the TSS indicate a more severe level of tuberculosis-related stigma.

    Time frame: Baseline, Post-Intervention, 3-month Post-Intervention, 6-month Post-Intervention, 1-year Post-Intervention

Secondary outcomes

  1. Mental Health, such as depression (Patient Health Questionnaire, PHQ-9)and anxiety (Generalized Anxiety Disorder Questionnaire, GAD-7)

    Patient Health Questionnaire-9 (PHQ-9) was used to assess the depressive symptoms of the participants in this study. The PHQ-9 is a validated, brief self-reported rating scale consisting of 9 items, which specifically targets the core diagnostic symptoms of depression. Each item is scored on a 4-point Likert scale, and the total score ranges from 0 to 27. Higher total scores indicate more severe depressive symptoms. Generalized Anxiety Disorder-7 (GAD-7) was utilized to evaluate the anxiety symptoms of the subjects. All 7 items are rated on a 4-point scoring system, with a total score ranging from 0 to 21. Higher scores represent more serious anxiety symptoms.

    Time frame: Baseline, Post-Intervention, 3-month Post-Intervention, 6-month Post-Intervention, 1-year Post-Intervention

  2. Health outcomes, such as sputum conversion rate and quality of life (EuroQol 5 Dimensions,EQ-5D)

    Extract patients' sputum smear and culture results from medical records. EuroQol 5 Dimensions (EQ-5D) was employed to evaluate the health-related quality of life of the participants in the present study. Each dimension of the EQ-5D is rated with a standardized response level, and the corresponding utility value is calculated to generate a final summary index score. The utility score ranges from 0.000 to 1.000, where 1.000 represents perfect health, a score of 0 indicates a state equivalent to death. Higher EQ-5D utility scores indicate better health-related quality of life.

    Time frame: Baseline, Post-Intervention, 3-month Post-Intervention, 6-month Post-Intervention, 1-year Post-Intervention

  3. Medication Adherence (8-item Morisky Medication Adherence Scale, MMAS-8)

    The 8-item Morisky Medication Adherence Scale (MMAS-8) was used to assess participants' medication adherence. This scale contains 8 items with a total score ranging from 0 to 8. Higher scores correspond to better medication adherence

    Time frame: Baseline, Post-Intervention, 3-month Post-Intervention, 6-month Post-Intervention, 1-year Post-Intervention

Other outcomes

  1. Intervention adherence and acceptability

    The usage rate, usage duration of the digital platform, and findings from qualitative interviews were used to assess participants' acceptability of the intervention.

    Time frame: Baseline, Post-Intervention, 3-month Post-Intervention, 6-month Post-Intervention, 1-year Post-Intervention

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07742683
Lead sponsor
Peking Union Medical College
Collaborators
Beijing Center for Disease Prevention and Control, Hainan Provincial Center for Disease Control and Prevention, Yichang Center for Disease Control and Prevention, China
Responsible party
Shu Jing (Ph.D. candidate, Peking Union Medical College) — Principal investigator
First posted
Aug 3, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion